Literature DB >> 17036250

[HIV-associated tumors].

A Potthoff1, N H Brockmeyer.   

Abstract

In the beginning of the HIV epidemic, Kaposi sarcoma was a common stigma in AIDS patients and one of the leading causes of death. While Kaposi sarcoma is seen less frequently since the introduction of antiretroviral therapy, lymphoma and other malignancies are an increasing therapeutic challenge. The incidence of HPV-related anal carcinoma and its precursor lesions is rising so dramatically that screening programs as they are already established for cervical carcinoma should be implemented. The role of HPV in UV-associated tumors is not yet determined. Additional risk factors like smoking and HCV co-infection seem to play important roles in the high incidence of lung and hepatocellular carcinomas. While fewer patients die from opportunistic infections, we face a growing problem with malignancies in HIV-positive patients.

Entities:  

Mesh:

Year:  2006        PMID: 17036250     DOI: 10.1007/s00105-006-1223-7

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  24 in total

1.  Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma.

Authors:  Eric Rosenthal; Isabelle Poizot-Martin; Thierry Saint-Marc; Jean-Philippe Spano; Patrice Cacoub
Journal:  Am J Clin Oncol       Date:  2002-02       Impact factor: 2.339

2.  Therapy of special HIV-associated diseases: HCV-HIV-co-infection and AIDS-related Kaposi's sarcoma - official satellite to the 7th European Conference on Clinical Aspects and Treatment of HIV-infection, October 23, 1999 in Lisbon, Portugal.

Authors:  F D Goebel; H Jablonowski
Journal:  Eur J Med Res       Date:  1999-12-16       Impact factor: 2.175

3.  Clinical spectrum and virologic characteristics of anal intraepithelial neoplasia in HIV infection.

Authors:  Alexander Kreuter; Norbert H Brockmeyer; Bettina Hochdorfer; Soenke J Weissenborn; Markus Stücker; Jochen Swoboda; Peter Altmeyer; Herbert Pfister; Ulrike Wieland
Journal:  J Am Acad Dermatol       Date:  2005-04       Impact factor: 11.527

Review 4.  Clinical manifestations and therapies of AIDS associated tumors.

Authors:  N Brockmeyer; B Barthel
Journal:  Eur J Med Res       Date:  1998-03-23       Impact factor: 2.175

Review 5.  Update on chronic hepatitis C in HIV/HCV-coinfected patients: viral interactions and therapy.

Authors:  Norbert Bräu
Journal:  AIDS       Date:  2003-11-07       Impact factor: 4.177

6.  HIV-related lung cancer in the era of highly active antiretroviral therapy.

Authors:  Mark Bower; Tom Powles; Mark Nelson; Pallav Shah; Sarah Cox; Sundhiya Mandelia; Brian Gazzard
Journal:  AIDS       Date:  2003-02-14       Impact factor: 4.177

7.  Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.

Authors:  A Gabizon; R Catane; B Uziely; B Kaufman; T Safra; R Cohen; F Martin; A Huang; Y Barenholz
Journal:  Cancer Res       Date:  1994-02-15       Impact factor: 12.701

8.  Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma.

Authors:  Anil Tulpule; Jerome Groopman; M Wayne Saville; William Harrington; Alvin Friedman-Kien; Byron M Espina; Carlos Garces; Lily Mantelle; Karl Mettinger; David T Scadden; Parkash S Gill
Journal:  Cancer       Date:  2002-07-01       Impact factor: 6.860

9.  A randomized prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma.

Authors:  K J Stelzer; T W Griffin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-12-01       Impact factor: 7.038

10.  Outcome of patients with HIV-related germ cell tumours: a case-control study.

Authors:  T Powles; M Bower; J Shamash; J Stebbing; J Ong; G Daugaard; A De Ruiter; M Johnson; M Fisher; J Anderson; M Nelson; B Gazzard; T Oliver
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

View more
  1 in total

Review 1.  [Skin tumours of the facial area].

Authors:  M Braun-Falco
Journal:  HNO       Date:  2009-04       Impact factor: 1.284

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.